When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
A significant portion of the Greenlandic Inuit population carries a genetic variant that increases their risk of type 2 diabetes tenfold. Now, researchers from the University of Copenhagen have ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product ... Tresiba made just over $1.1 billion last year, including ...
Insulin pump therapy ... which has been supported by Novo Nordisk, Medtronic, Roche Diagnostics, Boehringer Ingelheim, and Lilly through institutional research grants. R.W.H. has not received ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...
The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...